Physician profile
Norman A Gray
NPI 1437295698
$14,344.96
in general payments reported to CMS, 2019-2025
45 companies · $1,401 in 2025
The $1,401 reported for 2025 was more than what 77% of Cardiovascular Disease providers received nationally (typical 2025 total: $433).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $2,473 · 2020: $1,096 · 2021: $1,893 · 2022: $2,047 · 2023: $2,177 · 2024: $3,258 · 2025: $1,401.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $5,970 · Travel and Lodging: $867.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $5,969.86 |
| Travel and Lodging | $866.76 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Boston Scientific Corporation | $3,971.73 | 2019-2025 | Watchman Access System, Eluvia |
| Janssen Pharmaceuticals, INC | $1,160.11 | 2019-2024 | Xarelto |
| Amgen INC. | $1,076.39 | 2019-2025 | Repatha, Repatha |
| Abiomed | $944.18 | 2019-2021 | |
| Pfizer INC. | $913.95 | 2019-2025 | |
| Novartis Pharmaceuticals Corporation | $783.62 | 2019-2025 | |
| Boehringer Ingelheim Pharmaceuticals, INC. | $739.06 | 2019-2025 | Jardiance |
| E.R. Squibb & Sons, L.L.C. | $656.02 | 2019-2025 | Camzyos, Eliquis |
| Astrazeneca Pharmaceuticals LP | $563.72 | 2019-2025 | Wainua, Lokelma, Farxiga |
| Merck Sharp & Dohme LLC | $483.81 | 2021-2025 | Verquvo, Capvaxive |
| Sanofi-Aventis U.S. LLC | $304.14 | 2019-2024 | |
| Medtronic, INC. | $252.12 | 2022 | |
| Impulse Dynamics (USA) INC. | $247.02 | 2022-2023 | Optimizer |
| Baxter Healthcare | $224.09 | 2022 | |
| Heartflow, INC. | $197.99 | 2022-2025 | Ffrct |
Show all 45 companies
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Norman Gray listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.